II 

Calendar No. 443 

117TH CONGRESS 

2D SESSION H. R. 1193 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 9, 2021 

Received 

MAY 25, 2022 

Read twice and referred to the Committee on Health, Education, Labor, and 

Pensions 

JULY 12, 2022 

Reported by Mrs. MURRAY, with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

AN ACT 

To amend title IV of the Public Health Service Act to 

direct the Director of the National Institutes of Health, 

in consultation with the Director of the National Heart, 

Lung, and Blood Institute, to establish a program under 

which the Director of the National Institutes of Health 

shall support or conduct research on valvular heart disease, and for other purposes. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1193 RS

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Cardiovascular Ad5 vances in Research and Opportunities Legacy Act’’. 

6 SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE7 SEARCH. 

8 Subpart 2 of part C of title IV of the Public Health 

9 Service Act (42 U.S.C. 285b et seq.) is amended by insert10 ing after section 424C (42 U.S.C. 285b–7c) the following: 

11 ‘‘SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE12 SEARCH. 

13 ‘‘(a) IN GENERAL.—The Director of the National In14 stitutes of Health, in consultation with the Director of the 

15 Institute, shall support or conduct research regarding val16 vular heart disease. 

17 ‘‘(b) SUPPORT GUIDELINES.—The distribution of 

18 funding authorized under subsection (a) may be used to 

19 pursue the following outcomes: 

20 ‘‘(1) Using precision medicine and advanced 

21 technological imaging to generate data on individ22 uals with valvular heart disease. 

23 ‘‘(2) Identifying and developing a cohort of in24 dividuals with valvular heart disease and available 

25 data. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 1193 RS

1 ‘‘(3) Corroborating data generated through clin2 ical trials to develop a prediction model to distin3 guish individuals at high risk for sudden cardiac ar4 rest or sudden cardiac death from valvular heart dis5 ease. 

6 ‘‘(4) For other outcomes needed to acquire nec7 essary data on valvular heart disease. 

8 ‘‘(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not 

9 later than one year after the date of the enactment of this 

10 section, the Director of the Institute shall convene a work11 shop composed of subject matter experts and stakeholders 

12 to identify research needs and opportunities to develop 

13 prescriptive guidelines for treatment of individuals with 

14 mitral valve prolapse. 

15 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

16 purpose of carrying out this section, there is authorized 

17 to be appropriated $20,000,000 for each of fiscal years 

18 2022 through 2026.’’. 

19 SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL 

20 AND PREVENTION. 

21 Part B of title III of the Public Health Service Act 

22 (42 U.S.C. 243 et seq.) is amended by inserting after sec23 tion 312 the following section: 


kjohnson on DSK79L0C42PROD with BILLS
4 

•HR 1193 RS

1 ‘‘SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A 

2 RESULT OF VALVULAR HEART DISEASE. 

3 ‘‘(a) IN GENERAL.—The Secretary, acting through 

4 the Director of the Centers for Disease Control and Pre5 vention, may carry out projects to increase education, 

6 awareness, or diagnosis of valvular heart disease and to 

7 reduce the incidence of sudden cardiac death caused by 

8 valvular heart disease. Such projects may be carried out 

9 by the Secretary directly or through awards of grants or 

10 contracts to public or nonprofit private entities. The Sec11 retary may directly (or through such awards) provide tech12 nical assistance with respect to the planning, development, 

13 and operation of such projects. 

14 ‘‘(b) CERTAIN ACTIVITIES.—Upon availability of ap15 plicable data, projects carried out under subsection (a) 

16 may include— 

17 ‘‘(1) continuing the activities at the Division for 

18 Heart Disease and Stroke Prevention, including 

19 those related to valvular heart disease; 

20 ‘‘(2) broadening the awareness of the public 

21 concerning the risk factors for, the symptoms of, 

22 and the public health consequences of valvular heart 

23 disease; and 

24 ‘‘(3) enhancing surveillance of out-of-hospital 

25 cardiac arrests to improve patient outcomes. 


kjohnson on DSK79L0C42PROD with BILLS
5 

•HR 1193 RS

1 ‘‘(c) GRANT PRIORITIZATION.—The Secretary may, 

2 in awarding grants or entering into contracts pursuant to 

3 subsection (a), give priority to entities seeking to carry 

4 out projects that target populations most impacted by val5 vular heart disease. 

6 ‘‘(d) COORDINATION OF ACTIVITIES.—The Secretary 

7 shall ensure that activities under this section are coordi8 nated, as appropriate, with other agencies of the Public 

9 Health Service that carry out activities regarding valvular 

10 heart disease. 

11 ‘‘(e) BEST PRACTICES.—The Secretary, acting 

12 through the Director of the Centers for Disease Control 

13 and Prevention, shall— 

14 ‘‘(1) collect and analyze the findings of research 

15 conducted with respect to valvular heart disease; and 

16 ‘‘(2) taking into account such findings, publish 

17 on the website of the Centers for Disease Control 

18 and Prevention best practices for physicians and 

19 other health care providers who provide care to indi20 viduals with valvular heart disease.’’. 

21 SECTION 1. SHORT TITLE. 

22 This Act may be cited as the ‘‘Cardiovascular Ad23 vances in Research and Opportunities Legacy Act’’. 


kjohnson on DSK79L0C42PROD with BILLS
6 

•HR 1193 RS

1 SEC. 2. HHS VALVULAR HEART DISEASE ACTIVITIES. 

2 (a) IN GENERAL.—The Secretary of Health and 

3 Human Services (referred to in this section as the ‘‘Sec4 retary’’) shall, as appropriate, continue activities related 

5 to research, education, and awareness of valvular heart dis6 eases. 

7 (b) NIH RESEARCH RELATED TO VALVULAR HEART

8 DISEASES.— 

9 (1) IN GENERAL.—The Director of the National 

10 Institutes of Health, in consultation with the Director 

11 of the National Heart, Lung, and Blood Institute, 

12 may support or conduct research regarding valvular 

13 heart diseases. 

14 (2) SUPPORT FURTHER RESEARCH.—In order to 

15 improve information on, and understanding of, cau16 sation and risk factors for valvular heart diseases, re17 search conducted or supported under this subsection 

18 for such diseases may include the following: 

19 (A) Use of advanced technological imaging 

20 and other relevant methods to generate data re21 lated to valvular heart diseases. 

22 (B) Assessing potential risk factors for sud23 den cardiac arrest or sudden cardiac death from 

24 valvular heart diseases. 

25 (C) Other activities, as appropriate, in 

26 order to improve the availability of information 


kjohnson on DSK79L0C42PROD with BILLS
7 

•HR 1193 RS

1 on, and advance research related to, valvular 

2 heart diseases. 

3 (3) MITRAL VALVE PROLAPSE WORKSHOP.—Not 

4 later than one year after the date of enactment of this 

5 Act, the Director of the National Heart, Lung, and 

6 Blood Institute shall, as appropriate, convene a work7 shop composed of subject matter experts and stake8 holders to identify research needs and opportunities to 

9 develop recommendations for the identification and 

10 treatment of individuals with mitral valve prolapse, 

11 including such individuals who may be at risk for 

12 sudden cardiac arrest or sudden cardiac death. 

13 (c) PREVENTION ACTIVITIES TO IMPROVE AWARENESS

14 OF SUDDEN CARDIAC DEATH AS A RESULT OF VALVULAR

15 HEART DISEASES.— 

16 (1) IN GENERAL.—The Secretary may carry out 

17 activities to increase education and awareness of val18 vular heart diseases in order to reduce the incidence 

19 of sudden cardiac death caused by such diseases. The 

20 Secretary may— 

21 (A) award grants or contracts to public or 

22 nonprofit private entities to carry out activities 

23 under this subsection; and 


kjohnson on DSK79L0C42PROD with BILLS
8 

•HR 1193 RS

1 (B) may directly, or through grants or con2 tracts, provide technical assistance with respect 

3 to such activities. 

4 (2) CERTAIN ACTIVITIES.—Upon availability of 

5 applicable data, projects carried out under paragraph 

6 (1) may include— 

7 (A) continuing activities at the Centers for 

8 Disease Control and Prevention related to val9 vular heart diseases; 

10 (B) improving the awareness of the public 

11 concerning any risk factors for, the symptoms of, 

12 and the public health impact of, valvular heart 

13 diseases; and 

14 (C) improving the availability of public 

15 health data and information, as appropriate, re16 garding cardiac arrests related to valvular heart 

17 diseases. 

18 (3) GRANT PRIORITIZATION.—The Secretary 

19 may, in awarding grants or entering into contracts 

20 pursuant to paragraph (1), give priority to entities 

21 seeking to carry out projects for populations most im22 pacted by valvular heart diseases. 

23 (4) COORDINATION OF ACTIVITIES.—The Sec24 retary shall, as appropriate, ensure that activities 

25 under this section are coordinated with other agencies 


kjohnson on DSK79L0C42PROD with BILLS
9 

•HR 1193 RS

1 and offices of the Department of Health and Human 

2 Services that carry out activities regarding valvular 

3 heart diseases. 

4 (5) BEST PRACTICES.—The Secretary shall, as 

5 applicable and appropriate, identify and disseminate 

6 best practices for relevant health care providers re7 lated to valvular heart diseases. 

8 (d) AUTHORIZATION OF APPROPRIATIONS.—For pur9 poses of carrying out this section, there are authorized to 

10 be appropriated such sums as may be necessary for each 

11 of fiscal years 2023 through 2027. 


kjohnson on DSK79L0C42PROD with BILLS
Calendar No. 443 

117TH CONGRESS 

2D SESSION H. R. 1193 

AN ACT 

To amend title IV of the Public Health Service Act 

and for other purposes. or conduct research on valvular heart disease, of the National Institutes of Health shall support to establish a program under which the Director the National Heart, Lung, and Blood Institute, of Health, in consultation with the Director of to direct the Director of the National Institutes 

JULY 12, 2022 

Reported with an amendment 


kjohnson on DSK79L0C42PROD with BILLS